Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Xbrane Biopharma. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Xbrane Biopharma's earnings available for a low price, and how does
this compare to other companies in the same industry?
Xbrane Biopharma is not considered high growth as it is expected to be loss making for the next 1-3 years.
Xbrane Biopharma's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Xbrane Biopharma's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
A company's financial position is much like your own financial position,
it includes everything you own
The boxes below represent the relative size of what makes up
Xbrane Biopharma's finances.
The net worth of a company is the difference between its assets and liabilities.
Xbrane Biopharma is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
Xbrane Biopharma's cash and other short term assets cover its long term commitments.
This treemap shows a more detailed breakdown of
Xbrane Biopharma's finances. If any of them are yellow this
indicates they may be out of proportion and red means they relate to one of the
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
Low level of unsold assets.
Debt is covered by short term assets, assets are 3.5x debt.
Nearly all companies have debt. Debt in itself isn’t
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.
The graphic below shows equity (available funds) and debt, we ideally want to
see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and
whether the level has increased over the past 5 years.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Mr. Martin Åmark serves as the Head of Investor Relation since February 14, 2019 and also serves as Chief Executive Officer of Xbrane Biopharma AB (publ). Mr. Åmark has 8 years of experience from Bain & Co as a Management Consultant. At Bain, he worked mainly with M&A, strategy and organisation with Nordic clients across multiple industries, including life science and pharmaceuticals. Mr. Åmark holds a M Sc. in industrial engineering and management from Linköping Institute of Technology and an MBA from INSEAD.
Insufficient data for Martin to compare compensation growth.
Insufficient data for Martin to establish whether their remuneration is reasonable compared to companies of similar size in Sweden.
Management Team Tenure
Average tenure and age of the
management team in years:
The tenure for the Xbrane Biopharma management team is about average.
CEO & Head of Investor Relation
Co-Founder & Member of Scientific Advisory Board
Chief Financial Officer
COO, Head of Biosimilars & Deputy CEO
Chief Technology Officer
Interim Head of Production & Head of Controlled Release Generics
Head of Clinical Affairs
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The average tenure for the Xbrane Biopharma board of directors is less than 3 years, this suggests a new board.
Xbrane Biopharma AB (publ), a biopharmaceutical company, develops and manufactures biosimilars and generic long acting injectables. Its lead product candidates under development include Xlucane, a ranibizumab biosimilar for the treatment of age-related macular degeneration, diabetes related macular edema, diabetic retinopathy, and retinal vein occlusion; and Spherotide, a long-acting injectable with the active substance triptorelin for the treatment of prostate cancer, breast cancer, endometriosis, and myoma. The company is headquartered in Solna, Sweden.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.